214 related articles for article (PubMed ID: 31287704)
21. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
Amharar Y; Curtin V; Gallagher KH; Healy AM
Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139
[TBL] [Abstract][Full Text] [Related]
22. Impact of the Chain Length and Topology of the Acetylated Oligosaccharide on the Crystallization Tendency of Naproxen from Amorphous Binary Mixtures.
Minecka A; Tarnacka M; Jurkiewicz K; Hachuła B; Wrzalik R; Kamiński K; Paluch M; Kamińska E
Mol Pharm; 2021 Jan; 18(1):347-358. PubMed ID: 33355470
[TBL] [Abstract][Full Text] [Related]
23. Physical Stability of an Amorphous Sugar Matrix Dried From Methanol as an Amorphous Solid Dispersion Carrier and the Influence of Heat Treatment.
Takeda K; Sekitoh T; Fujioka A; Yamamoto K; Okamoto T; Matsuura T; Imanaka H; Ishida N; Imamura K
J Pharm Sci; 2019 Jun; 108(6):2056-2062. PubMed ID: 30677416
[TBL] [Abstract][Full Text] [Related]
24. Fast surface crystallization of amorphous griseofulvin below T g.
Zhu L; Jona J; Nagapudi K; Wu T
Pharm Res; 2010 Aug; 27(8):1558-67. PubMed ID: 20414704
[TBL] [Abstract][Full Text] [Related]
25. What Are the Important Factors That Influence API Crystallization in Miscible Amorphous API-Excipient Mixtures during Long-Term Storage in the Glassy State?
Newman A; Zografi G
Mol Pharm; 2022 Feb; 19(2):378-391. PubMed ID: 34378939
[TBL] [Abstract][Full Text] [Related]
26. Selecting Excipients Forming Therapeutic Deep Eutectic Systems-A Mechanistic Approach.
Wolbert F; Brandenbusch C; Sadowski G
Mol Pharm; 2019 Jul; 16(7):3091-3099. PubMed ID: 31095911
[TBL] [Abstract][Full Text] [Related]
27. Solubility of Pharmaceutical Ingredients in Natural Edible Oils.
Brinkmann J; Rest F; Luebbert C; Sadowski G
Mol Pharm; 2020 Jul; 17(7):2499-2507. PubMed ID: 32369379
[TBL] [Abstract][Full Text] [Related]
28. Investigation of Drug-Excipient Interactions in Biclotymol Amorphous Solid Dispersions.
Schammé B; Couvrat N; Tognetti V; Delbreilh L; Dupray V; Dargent É; Coquerel G
Mol Pharm; 2018 Mar; 15(3):1112-1125. PubMed ID: 29328661
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of amorphous celecoxib stability by mixing it with octaacetylmaltose: the molecular dynamics study.
Grzybowska K; Paluch M; Wlodarczyk P; Grzybowski A; Kaminski K; Hawelek L; Zakowiecki D; Kasprzycka A; Jankowska-Sumara I
Mol Pharm; 2012 Apr; 9(4):894-904. PubMed ID: 22384922
[TBL] [Abstract][Full Text] [Related]
30. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
31. Accelerated stability modeling of recrystallization from amorphous solid Dispersions: A Griseofulvin/HPMC-AS case study.
Leon AS; Waterman KC; Wang G; Wang L; Cai T; Zhang X
Int J Pharm; 2024 May; 657():124189. PubMed ID: 38701906
[TBL] [Abstract][Full Text] [Related]
32. Barrier coated drug layered particles for enhanced performance of amorphous solid dispersion dosage form.
Puri V; Dantuluri AK; Bansal AK
J Pharm Sci; 2012 Jan; 101(1):342-53. PubMed ID: 21935949
[TBL] [Abstract][Full Text] [Related]
33. Impact of Polymer Enrichment at the Crystal-Liquid Interface on Crystallization Kinetics of Amorphous Solid Dispersions.
Zhang J; Shi Q; Tao J; Peng Y; Cai T
Mol Pharm; 2019 Mar; 16(3):1385-1396. PubMed ID: 30716277
[TBL] [Abstract][Full Text] [Related]
34. Development of Maltodextrin-Based Immediate-Release Tablets Using an Integrated Twin-Screw Hot-Melt Extrusion and Injection-Molding Continuous Manufacturing Process.
Puri V; Brancazio D; Desai PM; Jensen KD; Chun JH; Myerson AS; Trout BL
J Pharm Sci; 2017 Nov; 106(11):3328-3336. PubMed ID: 28684263
[TBL] [Abstract][Full Text] [Related]
35. Amino acids as co-amorphous excipients for tackling the poor aqueous solubility of valsartan.
Huang Y; Zhang Q; Wang JR; Lin KL; Mei X
Pharm Dev Technol; 2017 Feb; 22(1):69-76. PubMed ID: 27050301
[TBL] [Abstract][Full Text] [Related]
36. Physical stability of API/polymer-blend amorphous solid dispersions.
Lehmkemper K; Kyeremateng SO; Bartels M; Degenhardt M; Sadowski G
Eur J Pharm Biopharm; 2018 Mar; 124():147-157. PubMed ID: 29269154
[TBL] [Abstract][Full Text] [Related]
37. Clozapine-carboxylic acid plasticized co-amorphous dispersions: Preparation, characterization and solution stability evaluation.
Ali AM; Ali AA; Maghrabi IA
Acta Pharm; 2015 Jun; 65(2):133-46. PubMed ID: 26011930
[TBL] [Abstract][Full Text] [Related]
38. Determination of drug-polymer solubility from supersaturated spray-dried amorphous solid dispersions: A case study with Efavirenz and Soluplus®.
Costa BLA; Sauceau M; Del Confetto S; Sescousse R; Ré MI
Eur J Pharm Biopharm; 2019 Sep; 142():300-306. PubMed ID: 31247317
[TBL] [Abstract][Full Text] [Related]
39. Micro-scale solubility assessments and prediction models for active pharmaceutical ingredients in polymeric matrices.
Bochmann ES; Neumann D; Gryczke A; Wagner KG
Eur J Pharm Biopharm; 2019 Aug; 141():111-120. PubMed ID: 31100430
[TBL] [Abstract][Full Text] [Related]
40. Crystal growth formation in melt extrudates.
Bruce C; Fegely KA; Rajabi-Siahboomi AR; McGinity JW
Int J Pharm; 2007 Aug; 341(1-2):162-72. PubMed ID: 17524578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
